Icon picks goBalto Activate to accelerate study startup
Icon is using goBalto’s flagship product, Activate, for all global studies spanning more than 50 countries. Icon is benefiting from Activate's robust library of country-specific workflows and management-based approach to site activation and already has integrated Activate with its CTMS and data warehouse, and has plans to integrate with its eTMF system.
Combining Icon’s improved processes and practices with Activate allows Icon to streamline study startup, provide real-time status updates to the entire clinical study team, and eliminate “hidden” communications created by relying on email and manual spreadsheets. Icon engages collaboratively with investigator sites using Activate to improve the communication process and to ultimately minimize the time to obtain critical documents.
Now with access to at-a-glance critical path study and country level reports, Icon brings enhanced service to its pharmaceutical, biotechnology and medical device clients.
Icon also is using goBalto’s Analyze module for reporting and providing insight across multiple studies and regions. Along with Activate, Analyze provides real-time visibility into study startup, making it easier to quantify team performance and discover meaningful patterns in study startup data.
Marie Keegan, vice president and global functional head, study start up at Icon, said, “Accelerating study startup timelines is a key component of our ICONIK Informatics Hub strategy, which combines industry leading technologies with best practices to help our clients take time and cost from their development programs. Following a comprehensive review of our study startup activities, we adopted a range of new processes and procedures that have streamlined our site activation. We supplemented this with the capabilities of goBalto's Activate and Analyze to drive our study startup process, and are seeing significant positive impact on cycle time, quality and productivity as a result.”
“The life sciences industry has recognized study startup as one of the worst-performing areas in clinical trials,” said Jae Chung, goBalto’s founder and president. “Icon is taking the lead in automating a cumbersome industry process, with the goal of getting medicines to those in need faster.”